Business
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by
About this update from Vaxcyte, Inc.
[{"type":"text","content":"FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors. Dr. Paya will also serve as the Board Chair. Kurt von Emster, a longtime director who served as Interim Chair, will remain on the board. “We are pleased to have Carlos and Michael join our board of directors to help us scale and advance our business to deliver next-generation vaccines, including VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV) candidate,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “Carlos, our new Chair, and Michael bring deep biopharmaceutical and vaccine expertise and will provide strategic insights across many aspects of our business, including R&D, commercialization, supply chain and manufacturing, as they have done for numerous companies.” “Vaxcyte is working to bring transformative innovation to vaccine development with the potential to achieve what other approaches have been unable to deliver,” said Dr. Paya. “I’m pleased to join in their effort to advance novel and superior vaccines for some of the most common and deadly infectious diseases worldwide, including pneumococcal disease for which the need for broader-spectrum vaccines continues to be critical.” Dr. Kamarck added, “Vaxcyte’s VAX-24 was designed to address the need for a PCV that can offer broader protection to prevent pneumococcal disease. As this program advances into clinical development, I look forward to sharing my knowledge about the worldwide commercialization and supply of vaccines, including PCVs.” About Carlos Paya Dr. Paya’s esteemed career spans over 30 years as a leading physician-scientist in immunology and a senior executive in the biopharmaceutical industry. He has broad leadership expertise in R&D, commercial readiness and product launches. Dr. Paya currently holds a number of board positions and serves as the Board Chairman for Fluidigm and Highlight Therapeutics. Most recently, Dr. Paya served as the CEO and President of Immune Design Corp., as they advanced their dual platforms fo...